Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data

Journal of the American Academy of Dermatology

Volumn 76, Issue 3, 2017, Pages 432-440.e17

  Strober, Bruce ^a   Leonardi, Craig ^b   Papp, Kim A ^c   Mrowietz, Ulrich ^d   Ohtsuki, Mamitaro ^e   Bissonnette, Robert ^f   Ferris, Laura K ^g   Paul, Carle ^h   Lebwohl, Mark ⁱ   Braun, Daniel K ^j   Mallbris, Lotus ^j   Wilhelm, Stefan ^j   Xu, Wen ^j   Ljungberg, Anders ^j   Acharya, Nayan ^j   Reich, Kristian ^k  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^b Central Dermatology PC   (United States)

^c K Papp Clinical Research and Probity Medical Research   (Canada)

^d UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^e JICHI MEDICAL UNIVERSITY   (Japan)

^f INNOVADERM RESEARCH   (Canada)

^g UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^h UNIVERSITÉ PAUL SABATIER   (France)

ⁱ MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^j ELI LILLY AND COMPANY   (United States)

^k SCIderm Clinical Research and Dermatologikum   (Germany)

more..

Author keywords

adverse events; etanercept; integrated analysis; interleukin 17A; ixekizumab; psoriasis; safety

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CREATINE KINASE; ETANERCEPT; IXEKIZUMAB; LIVER ENZYME; PLACEBO; DERMATOLOGICAL AGENT; MONOCLONAL ANTIBODY;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ADENOCARCINOMA; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL ABUSE; ALCOHOL INTOXICATION; ALLERGY; ANAPHYLAXIS; ANGINA PECTORIS; APATHY; APPENDICITIS; ARTERY EMBOLISM; ARTHRALGIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUTOMUTILATION; B CELL LYMPHOMA; BACKACHE; BASAL CELL CARCINOMA; BENIGN NEOPLASM; BRAIN INFARCTION; BRAIN ISCHEMIA; BREAST CANCER; BREAST CARCINOMA; BRONCHITIS; BRONCHOPNEUMONIA; CANDIDIASIS; CARDIOPULMONARY INSUFFICIENCY; CARDIOVASCULAR DISEASE; CELLULITIS; CEREBRAL ARTERY EMBOLISM; CEREBROVASCULAR ACCIDENT; CHOLECYSTITIS; CHOLELITHIASIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; COLON CANCER; CONFERENCE PAPER; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY ARTERY SPASM; COUGHING; CREATINE KINASE BLOOD LEVEL; CROHN DISEASE; DEEP VEIN THROMBOSIS; DEPRESSION; DIARRHEA; DISEASES; DIVERTICULITIS; DOUBLE BLIND PROCEDURE; DRUG EXPOSURE; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; EAR INFECTION; ECZEMA; ERYSIPELAS; FALLING; FATIGUE; FEMALE; FEVER; FOLLICULITIS; GASTROENTERITIS; HAND FRACTURE; HEADACHE; HEART ARREST; HEART INFARCTION; HEMATOLOGIC DISEASE; HEMIPARESIS; HEPATOBILIARY DISEASE; HUMAN; HYPERSENSITIVITY; HYPERSOMNIA; HYPERTENSION; INCIDENCE; INFESTATION; INFLUENZA; INGUINAL HERNIA; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE REACTION; INJURY; INSOMNIA; INTERVERTEBRAL DISC PROTRUSION; INTERVERTEBRAL DISK DISEASE; INTOXICATION; KIDNEY CANCER; KIDNEY CARCINOMA; KIDNEY DISEASE; LACERATION; LACUNAR STROKE; LATENT TUBERCULOSIS; LIP CARCINOMA; LIP SQUAMOUS CELL CARCINOMA; LIVER FUNCTION TEST; LIVER METASTASIS; LUNG EMBOLISM; LUNG METASTASIS; LUNG TUMOR; LYMPHATIC SYSTEM DISEASE; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASM; MATERNAL EXPOSURE; MELANOMA; MENTAL DISEASE; METABOLIC DISORDER; MIDDLE AGED; MOOD; MULTICENTER STUDY; MYALGIA; MYCOBACTERIUM TUBERCULOSIS COMPLEX; NAUSEA; NEPHROLITHIASIS; NEUROLOGIC DISEASE; NEUROPATHY; NEUTROPENIA; NEUTROPHIL COUNT; NON INSULIN DEPENDENT DIABETES MELLITUS; NON SMALL CELL LUNG CANCER; NUTRITIONAL DISORDER; OPTIC ISCHEMIC NEUROPATHY; OROPHARYNX PAIN; OSTEOARTHRITIS; PERIPHERAL EDEMA; PERSONAL EXPERIENCE; PHARYNGITIS; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PREGNANCY; PRIORITY JOURNAL; PROSTATE CANCER; PRURITUS; PSORIASIS; PSORIATIC ARTHRITIS; PUSTULAR PSORIASIS; RANDOMIZED CONTROLLED TRIAL; RASH; RECTUM CANCER; RECTUM CARCINOMA; RHINITIS; RHINOPHARYNGITIS; SCIATICA; SIDE EFFECT; SINUSITIS; SLEEP DISORDERED BREATHING; SMALL INTESTINE ADENOCARCINOMA; SMALL INTESTINE CARCINOMA; SQUAMOUS CELL CARCINOMA; SQUAMOUS CELL LUNG CARCINOMA; STAPHYLOCOCCUS INFECTION; SUICIDAL IDEATION; SUICIDE; SUICIDE ATTEMPT; SYNOVIAL SARCOMA; TAKOTSUBO CARDIOMYOPATHY; THRUSH; THYROID CANCER; THYROID PAPILLARY CARCINOMA; THYROID TUMOR; TINEA PEDIS; TONSIL CANCER; TRAFFIC ACCIDENT; TRANSITIONAL CELL CARCINOMA; TUBERCULIN TEST; ULCERATIVE COLITIS; UNSTABLE ANGINA PECTORIS; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT DISEASE; URINARY TRACT INFECTION; URTICARIA; VAGINA CANDIDIASIS; VASCULAR DISEASE; VULVA CANCER; WEIGHT REDUCTION; ADVERSE EFFECTS; CHEMICALLY INDUCED; CLINICAL TRIAL (TOPIC); COLITIS, ULCERATIVE; COMPARATIVE STUDY; INDUCTION CHEMOTHERAPY; MAINTENANCE CHEMOTHERAPY; MYOCARDIAL INFARCTION; NEOPLASMS; STROKE; TIME FACTOR;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; CANDIDIASIS; CLINICAL TRIALS AS TOPIC; COLITIS, ULCERATIVE; CROHN DISEASE; DERMATOLOGIC AGENTS; ETANERCEPT; FEMALE; HUMANS; INCIDENCE; INDUCTION CHEMOTHERAPY; MAINTENANCE CHEMOTHERAPY; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NEOPLASMS; PSORIASIS; STROKE; TIME FACTORS;

EID: 85007236662     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2016.09.026     Document Type: Conference Paper

References (47)

1. 1 Jacobs, A., Rosumeck, S., Nast, A., Systematic review on the maintenance of response during systemic antipsoriatic therapy. Br J Dermatol 173 (2015), 910–921.
2. 2 Mease, P.J., Armstrong, A.W., Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis. Drugs 74 (2014), 423–441.
3. 3 Mrowietz, U., Implementing treatment goals for successful long-term management of psoriasis. J Eur Acad Dermatol Venereol 26 Suppl 2 (2012), 12–20.
4. 4 Sandoval, L.F., Pierce, A., Feldman, S.R., Systemic therapies for psoriasis: an evidence-based update. Am J Clin Dermatol 15 (2014), 165–180.
5. 5 Archier, E., Devaux, S., Castela, E., et al. Carcinogenic risks of psoralen UV-A therapy and narrowband UV-B therapy in chronic plaque psoriasis: a systematic literature review. J Eur Acad Dermatol Venereol 26 Suppl 3 (2012), 22–31.
6. 6 Pathirana, D., Ormerod, A.D., Saiag, P., et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 23 Suppl 2 (2009), 1–70.
7. 7 Leonardi, C.L., Kimball, A.B., Papp, K.A., et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomized, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 371 (2008), 1665–1674.
8. 8 Leonardi, C.L., Powers, J.L., Matheson, R.T., et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 349 (2003), 2014–2022.
9. 9 Menter, A., Tyring, S.K., Gordon, K., et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol 58 (2008), 106–115.
10. 10 Papp, K.A., Langley, R.G., Lebwohl, M., et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomized, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 371 (2008), 1675–1684.
11. 11 Reich, K., Nestle, F.O., Papp, K., et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicenter, double-blind trial. Lancet 366 (2005), 1367–1374.
12. 12 Kimball, A.B., Pariser, D., Yamauchi, P.S., et al. OBSERVE-5 interim analysis: an observational postmarketing safety registry of etanercept for the treatment of psoriasis. J Am Acad Dermatol 68 (2013), 756–764.
13. 13 Menter, A., Thaci, D., Papp, K.A., et al. Five-year analysis from the ESPRIT 10-year postmarketing surveillance registry of adalimumab treatment for moderate to severe psoriasis. J Am Acad Dermatol 73 (2015), 410–419.e6.
14. 14 Papp, K., Gottlieb, A.B., Naldi, L., et al. Safety surveillance for ustekinumab and other psoriasis treatments from the psoriasis longitudinal assessment and registry (PSOLAR). J Drugs Dermatol 14 (2015), 706–714.
15. 15 Papp, K.A., Griffiths, C.E., Gordon, K., et al. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up. Br J Dermatol 168 (2013), 844–854.
16. 16 Shear, N.H., Hartmann, M., Toledo-Bahena, M., et al. Long-term efficacy and safety of infliximab maintenance therapy in patients with plaque-type psoriasis in real-world practice. Br J Dermatol 171 (2014), 631–641.
17. 17 Langley, R.G., Elewski, B.E., Lebwohl, M., et al. Secukinumab in plaque psoriasis–results of two phase 3 trials. N Engl J Med 371 (2014), 326–338.
18. 18 Thaci, D., Blauvelt, A., Reich, K., et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol 73 (2015), 400–409.
19. 19 Griffiths, C.E., Reich, K., Lebwohl, M., et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomized trials. Lancet 386 (2015), 541–551.
20. 20 Gordon, K.B., Blauvelt, A., Papp, K.A., et al. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. New England Journal of Medicine 375 (2016), 345–356.
21. 21 Lebwohl, M., Strober, B., Menter, A., et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med 373 (2015), 1318–1328.
22. 22 Papp, K., Leonardi, C., Menter, A., et al. Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment. J Am Acad Dermatol 71 (2014), 1183–1190.e3.
23. 23 Gordon, K.B., Leonardi, C.L., Lebwohl, M., et al. A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis. J Am Acad Dermatol 71 (2014), 1176–1182.
24. 24 Krueger, J.G., Fretzin, S., Suarez-Farinas, M., et al. IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis. J Allergy Clin Immunol 130 (2012), 145–154.e9.
25. 25 Leonardi, C., Matheson, R., Zachariae, C., et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med 366 (2012), 1190–1199.
26. 26 Saeki, H., Nakagawa, H., Ishii, T., et al. Efficacy and safety of open-label ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis. J Eur Acad Dermatol Venereol 29 (2015), 1148–1155.
27. 27 Mantel, N., Chi-square tests with one degree of freedom; extensions of the Mantel-Haenszel procedure. J Am Stat Assoc 58 (1963), 690–700.
28. 28 Long, J.S., 1st ed. Regression models for categorical and limited dependent variables. Advanced quantitative techniques in the social sciences, Number 7, 1997, Sage Publications, Thousand Oaks, CA.
29. 29 Puel, A., Cypowyj, S., Bustamante, J., et al. Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity. Science 332 (2011), 65–68.
30. 30 Cypowyj, S., Picard, C., Marodi, L., et al. Immunity to infection in IL-17-deficient mice and humans. Eur J Immunol 42 (2012), 2246–2254.
31. 31 Gaffen, S.L., Hernandez-Santos, N., Peterson, A.C., IL-17 signaling in host defense against Candida albicans. Immunol Res 50 (2011), 181–187.
32. 32 Peck, A., Mellins, E.D., Precarious balance: Th17 cells in host defense. Infect Immun 78 (2010), 32–38.
33. 33 Stevens, D.L., Bryant, A.E., Impetigo, erysipelas and cellulitis. Ferretti, J.J., Stevens, D.L., Fischetti, V.A., (eds.) Streptococcus pyogenes: basic biology to clinical manifestations, 2016, University of Oklahoma Health Sciences Center, Oklahoma City (OK), 1–15.
34. 34 Centers for Disease Control and Prevention. Updated guidelines for using interferon gamma release assays to detect Mycobacterium tuberculosis infection — United States, 2010. MMWR Recomm Rep 59:RR-5 (2010), 1–28.
35. 35 Canadian tuberculosis standards. 7th ed. Public Health Agency of Canada. 2014;469:1-468.
36. 36 Tsiouri, G., Gaitanis, G., Kiorpelidou, D., et al. Tuberculin skin test overestimates tuberculosis hypersensitivity in adult patients with psoriasis. Dermatology 219 (2009), 119–125.
37. 37 Fiorentino, D., Langley, R., Fakharzadeh, S., et al. Malignancy events in the psoriasis longitudinal assessment and registry (PSOLAR) study: current status of observations. J Am Acad Dermatol, 2014, AB175 Abstract P8155.
38. 38 Kimball, A.B., Schenfeld, J., Accortt, N.A., et al. Incidence rates of malignancies and hospitalized infectious events in patients with psoriasis with or without treatment and a general population in the U.S.A.: 2005-09. Br J Dermatol 170 (2014), 366–373.
39. 39 Margolis, D., Bilker, W., Hennessy, S., et al. The risk of malignancy associated with psoriasis. Arch Dermatol 137 (2001), 778–783.
40. 40 Haynes, K., Beukelman, T., Curtis, J.R., et al. Tumor necrosis factor alpha inhibitor therapy and cancer risk in chronic immune-mediated diseases. Arthritis Rheum 65 (2013), 48–58.
41. 41 Makredes, M., Robinson, D. Jr., Bala, M., Kimball, A.B., The burden of autoimmune disease: a comparison of prevalence ratios in patients with psoriatic arthritis and psoriasis. J Am Acad Dermatol 61 (2009), 405–410.
42. 42 Wu, J.J., Nguyen, T.U., Poon, K.Y., Herrinton, L.J., The association of psoriasis with autoimmune diseases. J Am Acad Dermatol 67 (2012), 924–930.
43. 43 Li, W.Q., Han, J.L., Chan, A.T., Qureshi, A.A., Psoriasis, psoriatic arthritis and increased risk of incident Crohn's disease in US women. Ann Rheum Dis 72 (2013), 1200–1205.
44. 44 Egeberg, A., Mallbris, L., Warren, R.B., et al. Association between psoriasis and inflammatory bowel disease - a Danish nationwide cohort study. Br J Dermatol 175 (2016), 487–492.
45. 45 Hueber, W., Sands, B.E., Lewitzky, S., et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomized, double-blind placebo-controlled trial. Gut 61 (2012), 1693–1700.
46. 46 Mozaffari, S., Nikfar, S., Abdollahi, M., Inflammatory bowel disease therapies discontinued between 2009 and 2014. Expert Opin Investig Drugs 24 (2015), 949–956.
47. 47 Kurd, S.K., Troxel, A.B., Crits-Christoph, P., et al. The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study. Arch Dermatol 146 (2010), 891–895.